OHSU is still looking for a few more participants for its Pramlintide Study.  The study is testing how well a new closed loop system, called iPancreas, manages blood sugars in people with type 1 diabetes (T1D) using Omnipods with insulin plus pramlintide.  Pramlintide works by slowing down the movement of food through the stomach, which prevents blood sugar from rising too high after a meal. Pramlintide is already FDA-approved for T1D when used with mealtime insulin.

The closed loop system will receive glucose values from the Dexcom G6 continuous glucose monitoring (CGM) and automatically send commands to one Omnipod for insulin and one Omnipod for pramlintide.

Both pump and MDI users may be eligible.

The study will take place over ~6 weeks and consists of 4 visits:  a 1.5 hour screening visit, a short visit for training on using the Dexcom G6 CGM with the study app, a 12.5 hour in-clinic visit to use both insulin and pramlintide, and a 12.5 hour in-clinic visit to use only insulin.  During the 12.5 hour in-clinic visits, participants will eat breakfast and lunch in the clinic.

To learn more about this study or find out if you’re eligible, please contact one of the following or scan the QR code:

Oregon Health and Science University | Portland, Oregon
Phone: 503-418-9070
Email: oregonapc@ohsu.edu